Pharming licenses orphan drug from Novartis
Pharming NV has paid €17.9m upfront to Novartis AG for an exclusive license to CDZ173, a late stage drug for the treatment of APDS
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
New stem cell population may help repair teeth
Researchers have discovered that crosstalk of a newly discovered stem cell population with quiescent stem cells may help repair teeth in the future.
Bayer bags iPSC specialist BlueRock Therapeutics
Bayer has widened its pipeline in neurology, cardiology, and immunology by acquiring induced pluripotent stem cell specialist BlueRock Therapeutics.
Liquid biopsy identifies residual breast cancer
Using a platform tailored to patients’ specific cancer mutations, British and US researchers for the first time detected residual disease in breast cancer patients.
Novo Holdings puts $72m in Lanzatech
Novo Holdings A/S (Novo Holdings) invests $72m in LanzaTech to support development of the company’s sustainable fuels and chemicals platform
Google maps for tumours and organs
Transgene’s licenced oncolytic virus fails in Phase III
SillaJen, the licensor for French immunoncology specialist Transgene SA, has stopped enrolment into the Phase III Phocus trial after an Independent Data Review Comittee predicted the study endpoint won’t be met.
Wellington Partners launch €210m Life Sciences fund
Wellington Partners has closed its largest Life Sciences Fund ever. The VC specialist outperformed its intial target of raising €120m to €150m and closed at €210m.
Alizé Pharma 3 bags largest EU financing so far
Venture Captital specialist LSP led a €67m Series A financing in peptide developer Alizé Pharma 3.
Better TNF? receptor blockers on the horizon
Two research teams have unraveled the complex dynamics of TNF? receptor signaling and have identified compounds that may be safer than current treatments.